Many efforts have been made to achieve targeted delivery of anticancer drugs to enhance
their efficacy and to reduce their adverse effects. These efforts include the development of …

Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a
patient despite the concurrent use of 3 antihypertensive drug classes, commonly including a …

Cardiovascular disease (CVD) is the leading cause of mortality in people with type 2
diabetes mellitus (T2DM), yet a significant proportion of the disease burden cannot be …

e2 Hypertension February 2018 target> 1 kinase receptor allowing for a broader indication
for use but with a greater potential for off-target effects. VSP inhibitors have been …

Cardiovascular (CV) toxicity is a potential short-or long-term complication of various
anticancer therapies. Some drugs, such as anthracyclines or other biological agents, have …

Secondary hypertension refers to arterial hypertension due to an identifiable cause and
affects∼ 5–10% of the general hypertensive population. Because secondary forms are rare …

The thin layer of cells that lines the interior of blood vessels, known as the endothelium,
plays a complex role in vascular biology. The endothelium mediates blood vessel tone …

The development of a wide range of novel antineoplastic therapies has improved the
prognosis for patients with a wide range of malignancies, which has increased the number …

The skin interstitium sequesters excess Na+ and Cl–in salt-sensitive hypertension.
Mononuclear phagocyte system (MPS) cells are recruited to the skin, sense the hypertonic …

Hypertension is a mechanism-based toxic effect of drugs that inhibit the vascular endothelial
growth factor signaling pathway (VSP). Substantial evidence exists for managing …